You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):脂肪靶向、每月一次注射的小分子THRβ激動劑ASC47聯合司美格魯肽治療肥胖症的美國臨牀研究完成所有受試者給藥
格隆匯 07-15 06:55

格隆匯7月15日丨歌禮制藥-B(01672.HK)發佈公吿,評估超長效皮下注射ASC47單次給藥聯合司美格魯肽在不伴有2型糖尿病的肥胖受試者中的安全性、耐受性以及在第29天的初步療效的隨機、雙盲、安慰劑對照研究(ASC47-103研究,NCT06972992)已於近期完成所有28例受試者給藥。28例受試者入組於兩個月內快速完成。ASC47-103研究在美國開展,共設3個隊列,受試者接受ASC47單劑量遞增(10毫克、30毫克和60毫克)或注射等量(volume-matched)安慰劑。各隊列受試者還接受四次司美格魯肽(0.5毫克,每週一次)給藥。

“ASC47臨牀入組推進如此之快,凸顯了業界對減重新療法以及聯合用藥潛在優勢的濃厚興趣。”歌禮制藥創始人、董事會主席兼首席執行官吳勁梓博士表示,“該試驗正如期穩步推進,預計將於2025年第四季度獲得其頂線數據。”

ASC47是一款由歌禮自主研發的、脂肪靶向、超長效皮下注射的甲狀腺激素受體β(THRβ)選擇性小分子激動劑。ASC47具有獨特的差異化特性,能夠靶向脂肪,從而在脂肪組織中產生劑量依賴性的高藥物濃度。預計將於2025年第四季度獲得ASC47和司美格魯肽聯合用藥研究的頂線數據。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account